| Quarter (USD) | Sep 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 19.13 mm | 19.13 mm | 19.13 mm | 19.13 mm | 19.13 mm | 19.13 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 2.61 mm | 2.70 mm | (no burn) | 1.53 mm |
| Cash used (since last report) | n/a | n/a | 7.30 mm | 7.57 mm | n/a | 4.27 mm |
| Cash remaining | n/a | n/a | 11.83 mm | 11.56 mm | n/a | 14.86 mm |
| Runway (months of cash) | n/a | n/a | 4.5 | 4.3 | n/a | 9.7 |
| 13F holders | Current |
|---|---|
| Total holders | 32 |
| Opened positions | 3 |
| Closed positions | 15 |
| Increased positions | 7 |
| Reduced positions | 13 |
| 13F shares | Current |
|---|---|
| Total value | 41.79 mm |
| Total shares | 20.66 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Cambrian BioPharma | 5.23 mm | $30.34 mm |
| James Peyer | 4.69 mm | $0.00 |
| H&S Investments I | 4.44 mm | $0.00 |
| Apeiron Investment | 3.44 mm | $7.02 mm |
| Ra Capital Management | 683.53 k | $1.06 mm |
| Vanguard | 573.46 k | $889.00 k |
| Newtyn Management | 415.00 k | $643.00 k |
| Renaissance Technologies | 205.80 k | $319.00 k |
| BLK BlackRock | 173.95 k | $270.00 k |
| Bridgeway Capital Management | 162.90 k | $252.00 k |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 Dec 24 | Stephanie Krebs | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4499 | 120,000 | 53.99 k | 120,000 |
| 20 Dec 24 | der Horst Edward van | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4499 | 100,000 | 44.99 k | 100,000 |
| 20 Dec 24 | Josiah Craver | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4499 | 100,000 | 44.99 k | 100,000 |
| 20 Dec 24 | John Celebi | Stock Option Common Stock | Grant | Acquire A | No | No | 0.4499 | 355,000 | 159.71 k | 355,000 |
